Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

被引：0
|
作者：
Cohen, Stanley [1 ]
Czeloth, Niklas [2 ]
Lees, Eric [3 ]
Klimiuk, Piotr A. [4 ,5 ]
Peter, Nuala [6 ]
Jayadeva, Girish [2 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Inland Rheumatol, Upland, CA USA
[4] Med Univ Bialystok, Bialystok, Poland
[5] Gabinet Internistyczno Reumatol, Bialystok, Poland
[6] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2522
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 104-WEEK RESULTS FROM THE FORTIFY STUDY
    Panaccione, Remo
    Rubin, David T.
    Loftus, Edward V.
    Lim, Allen
    Duan, W. Rachel
    Neimark, Ezequiel
    Song, Alexandra P.
    Kalabic, Jasmina
    Zambrano, Javier A.
    Kligys, Kristina
    Liao, Xiaomei
    Koetse, Willem
    Hisamatsu, Tadakazu
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    D'Haens, Geert
    Ferrante, Marc
    GASTROENTEROLOGY, 2023, 164 (06) : S1098 - S1099
  • [32] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
    Roy M. Fleischmann
    Daniel F. Alvarez
    Amy E. Bock
    Carol Cronenberger
    Ivana Vranic
    Wuyan Zhang
    Rieke Alten
    Arthritis Research & Therapy, 23
  • [33] Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn's disease and inadequate response to ustekinumab: Phase 2 GALAXI 1 study long-term extension results
    Afzali, A.
    Wolf, D.
    Leong, R.
    Salese, L.
    Gao, L. L.
    Busse, C.
    Panes, J.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1690 - i1691
  • [34] Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn's Disease and Inadequate Response to Ustekinumab: Phase 2 GALAXI 1 Study Long-Term Extension Results
    Afzali, Anita
    Wolf, Douglas
    Leong, Rupert
    Salese, Leonardo
    Gao, Long-Long
    Busse, Christopher
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1023 - S1024
  • [35] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial
    Fleischmann, Roy M.
    Alvarez, Daniel F.
    Bock, Amy E.
    Cronenberger, Carol
    Vranic, Ivana
    Zhang, Wuyan
    Alten, Rieke
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [36] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Alan Kivitz
    Alvin F. Wells
    Juan I. Vargas
    Herbert S. B. Baraf
    Maureen Rischmueller
    Justin Klaff
    Nasser Khan
    Yihan Li
    Kyle Carter
    Alan Friedman
    Patrick Durez
    Rheumatology and Therapy, 2023, 10 : 901 - 915
  • [37] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, Alan
    Wells, Alvin F.
    Vargas, Juan I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY, 2023, 62
  • [38] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Kivitz, Alan
    Wells, Alvin F. F.
    Vargas, Juan I. I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 901 - 915
  • [39] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, A.
    Wells, A. F.
    Vargas, J. Ignacio
    Baraf, H. S. B.
    Rischmueller, M.
    Klaff, J.
    Khan, N.
    Li, Y.
    Carter, K.
    Friedman, A.
    Durez, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 620 - 621
  • [40] Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
    Fleischmann, Roy
    Swierkot, Jerzy
    Penn, Sara K.
    Durez, Patrick
    Bessette, Louis
    Bu, Xianwei
    Khan, Nasser
    Li, Yihan
    Peterfy, Charles G.
    Tanaka, Yoshiya
    Mysler, Eduardo
    RMD OPEN, 2024, 10 (02):
12345